Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 9/20 | 0.74 |
| ▸ | POLB | P06746 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335348 | 0.87 | RAB9A (0.66) | POLBALDH1A1SMN1; SMN2HPGDLMNA | |
| Mofoxime SCHEMBL2734610 | 0.87 | FKBP1A (0.67) | FKBP1APOLBALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL13534672 | 0.85 | FKBP1A (0.92) | FKBP1APOLBALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL9041797 | 0.84 | ALDH1A1 (0.74) | FKBP1APOLBALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL15134834 | 0.84 | POLB (0.68) | POLBALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL11659648 | 0.83 | SMN1; SMN2 (0.70) | FKBP1APOLBALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL653789 | 0.83 | TPSAB1 (0.72) | FKBP1APOLBALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL12359393 | 0.83 | FKBP1A (1.00) | FKBP1APOLBALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL2712996 | 0.82 | FKBP1A (0.74) | FKBP1APOLBALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL15919449 | 0.82 | FKBP1A (0.74) | FKBP1APOLBALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
| US-4105790-A | ANTICOAGULANTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | FKBP1A 2222/4885POLB 3348/4885ALDH1A1 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.